The principal objectives of this grant are to secure funding to support the clinical research activity of the Eastern Cooperative Oncology Group (ECOG) at Vanderbilt University Medical Center, to facilitate patient accrual to ECOG trials, and to expand the scientific and administrative contributions made to ECOG by Vanderbilt investigators.
The specific aims of the proposal are: 1) to increase participation in ECOG sponsored clinical trials, 2) to further increase the scientific and administrative contributions to ECOG by Vanderbilt investigators, 3) to continue the development of innovative treatment programs for common solid tumors and hematologic malignancies, 4) to provide basic science expertise for correlative laboratory projects attached to ECOG trials and 5) to maintain a high level of data quality and management for which this institution is known. These goals will be achieved through the close interaction of investigators from medical oncology, radiation oncology, pathology and the section of surgical sciences. The interactions between Vanderbilt and other ECOG institutions will be facilitated by the presence of Vanderbilt investigators on ECOG disease oriented and modality committees. The Vanderbilt-lngram Comprehensive Cancer Center has in place all the necessary elements for the successful execution of cooperative group clinical trials including an outstanding data management staff, excellent outpatient and inpatient facilities in which this work will be undertaken and a long history of cooperative group participation.
|Williams, Michael E; Hong, Fangxin; Gascoyne, Randy D et al. (2016) Rituximab extended schedule or retreatment trial for low tumour burden non-follicular indolent B-cell non-Hodgkin lymphomas: Eastern Cooperative Oncology Group Protocol E4402. Br J Haematol 173:867-75|
|Moots, Paul L; O'Neill, Anne; Londer, Harold et al. (2016) Preradiation Chemotherapy for Adult High-risk Medulloblastoma: A Trial of the ECOG-ACRIN Cancer Research Group (E4397). Am J Clin Oncol :|
|Haas, Naomi B; Manola, Judith; Uzzo, Robert G et al. (2016) Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial. Lancet 387:2008-16|
|Wagner, Lynne I; Zhao, Fengmin; Hong, Fangxin et al. (2015) Anxiety and health-related quality of life among patients with low-tumor burden non-Hodgkin lymphoma randomly assigned to two different rituximab dosing regimens: results from ECOG trial E4402 (RESORT). J Clin Oncol 33:740-8|
|Ciombor, Kristen K; Feng, Yang; Benson 3rd, Al Bowen et al. (2014) Phase II trial of bortezomib plus doxorubicin in hepatocellular carcinoma (E6202): a trial of the Eastern Cooperative Oncology Group. Invest New Drugs 32:1017-27|
|Kahl, Brad S; Hong, Fangxin; Williams, Michael E et al. (2014) Rituximab extended schedule or re-treatment trial for low-tumor burden follicular lymphoma: eastern cooperative oncology group protocol e4402. J Clin Oncol 32:3096-102|
|Gonsalves, Wilson I; Mahoney, Michelle R; Sargent, Daniel J et al. (2014) Patient and tumor characteristics and BRAF and KRAS mutations in colon cancer, NCCTG/Alliance N0147. J Natl Cancer Inst 106:|
|Hodi, F Stephen; Lee, Sandra; McDermott, David F et al. (2014) Ipilimumab plus sargramostim vs ipilimumab alone for treatment of metastatic melanoma: a randomized clinical trial. JAMA 312:1744-53|
|Huang, Jocelin; Nair, Suresh G; Mahoney, Michelle R et al. (2014) Comparison of FOLFIRI with or without cetuximab in patients with resected stage III colon cancer; NCCTG (Alliance) intergroup trial N0147. Clin Colorectal Cancer 13:100-9|
|Slingluff Jr, Craig L; Lee, Sandra; Zhao, Fengmin et al. (2013) A randomized phase II trial of multiepitope vaccination with melanoma peptides for cytotoxic T cells and helper T cells for patients with metastatic melanoma (E1602). Clin Cancer Res 19:4228-38|
Showing the most recent 10 out of 76 publications